MedTrace Logo

Pumilio1 (PUM1) Expression, Sickle Cell Anemia, β-thalassemia Intermedia

NCT05883254 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-05-31

No results posted yet for this study

Summary

1. To study the expression pattern of PUM1 gene in patients with sickle cell anemia and β-thalassemia intermedia.
2. To detect PUM1 protein levels in sickle cell anemia and β-thalassemia intermedia patients.
3. To correlate PUM1 gene expression pattern and protein levels with HbF levels in sickle cell anemia and β-thalassemia intermedia patients.

Conditions

  • Sickle Cell Disease, Beta Thalassemia Intermedia

Interventions

DIAGNOSTIC_TEST

RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR

Quantatative Real -Time PCR for quantification of PUM1; * The type of the recruited samples: Ethylenediamine tetra-acetic acid (EDTA) peripheral blood samples. * The method of total RNA extraction: TRIzol and TRIzol LS. * The purity and concentration of the RNA were measured using a Nano Drop 2000 instrument. * cDNA was amplified with primers using the GoScript Reverse Transcription system. Western Blotting Assay of PUM1 protein levels

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2026-12-31
Completion
2027-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05883254 on ClinicalTrials.gov